AI Article Synopsis
- CYP2C9 and CYP2C19 are crucial enzymes that break down about 18% of drugs, including antihypertensives and anticonvulsants.
- There are many genetic variations (30 for CYP2C9 and 21 for CYP2C19) that can affect how different people metabolize these drugs.
- These genetic differences can vary significantly between ethnic groups and have important clinical implications, which the review aims to summarize.
Article Abstract
CYP2C9 and CYP2C19 are important drug metabolizing enzymes and together metabolize about 18% of currently available drugs. Some of the important groups of drugs that are metabolized by them are antihypertensives, hypoglycemics, anticonvulsants, antiulcer drugs etc. Genes encoding these enzymes are polymorphically expressed. Thirty variant alleles for CYP2C9 and 21 for CYP2C19 have been reported. The frequencies of these polymorphic alleles show marked inter-ethnic variation. Several reports have been published showing the clinical importance of this polymorphism. This review summarizes the currently available important information on this topic.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/157488407779422302 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!